Towards evidence-based combinations of approved and novel cancer drugs

Informazioni relative al progetto

onCOMBINE

ID dell’accordo di sovvenzione: 740469

DOI

10.3030/740469

Progetto chiuso

Data della firma CE 11 Settembre 2017

Data di avvio 1 Ottobre 2017

Data di completamento 30 Giugno 2023

Finanziato da

• EXCELLENT SCIENCE - European Research Council (ERC)

Costo totale

€ 2 488 306,00

Contributo UE

€ 2 488 306,00

Coordinato da

WEIZMANN INSTITUTE OF SCIENCE
Israel

CORDIS fornisce collegamenti ai risultati finali pubblici e alle pubblicazioni dei progetti ORIZZONTE.

I link ai risultati e alle pubblicazioni dei progetti del 7° PQ, così come i link ad alcuni tipi di risultati specifici come dataset e software, sono recuperati dinamicamente da .OpenAIRE .

Pubblicazioni

Peer reviewed articles (5)

Upfront admixing antibodies and EGFR inhibitors preempts sequential treatments in lung cancer models

Autori: Ilaria Marrocco, Donatella Romaniello, Itay Vaknin, Diana Drago-Garcia, Roni Oren, Mary Luz Uribe, Nishanth Belugali Nataraj, Soma Ghosh, Raya Eilam , Tomer-Meir Salame, Moshit Lindzen, Yosef Yarden 
Pubblicato in: EMBO Molecular Medicine, 2021, ISSN 1757-4684
Editore: Chichester Wiley Europe
DOI: 10.15252/emmm.202013144

AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer

Autori: Ashish Noronha, Nishanth Belugali Nataraj, Joo Sang Lee, Benny Zhitomirsky, Yaara Oren, Sara Oster, Moshit Lindzen, Saptaparna Mukherjee, Rainer Will, Soma Ghosh, Arturo Simoni-Nieves, Aakanksha Verma, Rishita Chatterjee, Simone Borgoni, Welles Robinson, Sanju Sinha, Alexander Brandis, D. Lucas Kerr, Wei Wu, Arunachalam Sekar, Suvendu Giri, Youngmin Chung, Diana Drago-Garcia, Brian P. Danysh, Matt
Pubblicato in: Cancer Discovery, 2022, Pagina/e 2666–2683, ISSN 2159-8290
Editore: American Association for Cancer Research
DOI: 10.1158/2159-8290.cd-22-0111

A Combination of Approved Antibodies Overcomes Resistance of Lung Cancer to Osimertinib by Blocking Bypass Pathways

Autori: D. Romaniello, L. Mazzeo, M. Mancini, I. Marrocco, A. Noronha, M. Kreitman, S. Srivastava, S. Ghosh, M. Lindzen, T.M. Salame, A. Onn, J. Barr, Y. Yarden
Pubblicato in: Clinical Cancer Research, Numero November 15, 2018, 2018, Pagina/e 5610-5621, ISSN 1557-3265
Editore: AACR
DOI: 10.1158/1078-0432.ccr-18-0450

An oligoclonal antibody durably overcomes resistance of lung cancer to third‐generation EGFR inhibitors

Autori: Maicol Mancini, Hilah Gal, Nadège Gaborit, Luigi Mazzeo, Donatella Romaniello, Tomer Meir Salame, Moshit Lindzen, Georg Mahlknecht, Yehoshua Enuka, Dominick GA Burton, Lee Roth, Ashish Noronha, Ilaria Marrocco, Dan Adreka, Raya Eilam Altstadter, Emilie Bousquet, Julian Downward, Antonio Maraver, Valery Krizhanovsky, Yosef Yarden
Pubblicato in: EMBO Molecular Medicine, Numero 10/2, 2018, Pagina/e 294-308, ISSN 1757-4676
Editore: John Wiley & Sons Ltd.
DOI: 10.15252/emmm.201708076

Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor

Autori: Donatella Romaniello, Ilaria Marrocco, Nishanth Belugali Nataraj, Irene Ferrer, Diana Drago-Garcia, Itay Vaknin, Roni Oren, Moshit Lindzen, Soma Ghosh, Matthew Kreitman, Jeanette Clarissa Kittel, Nadege Gaborit, Gretchen Bergado Baez, Belinda Sanchez, Raya Eilam, Eli Pikarsky, Luis Paz-Ares, Yosef Yarden
Pubblicato in: Cancers, Numero 12/9, 2020, Pagina/e 2394, ISSN 2072-6694
Editore: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/cancers12092394

Non-peer reviewed articles (2)

Host-Dependent Phenotypic Resistance to EGFR Tyrosine Kinase Inhibitors

Autori: Yuya Haga , Ilaria Marrocco , Ashish Noronha , Mary Luz Uribe , Nishanth Belugali Nataraj , Arunachalam Sekar , Diana Drago-Garcia, Simone Borgoni, Moshit Lindzen , Suvendu Giri , Stefan Wiemann , Yasuo Tsutsumi , Yosef Yarden
Pubblicato in: CANCER RESEARCH, 2021, ISSN 0008-5472
Editore: American Association for Cancer Research
DOI: 10.1158/0008-5472.can-20-3555

PD-L1 recruits phospholipase C and enhances tumorigenicity of lung tumors harboring mutant forms of EGFR

Autori: Soma Ghosh, Nishanth Bulugali Nataraj, Ashish Noronha, Sushant Patkar, Arunachalam Sekar, Saptaparna Mukherjee, Sabina, Winograd-Katz, Lior Kramarski, Aakanksha Verma, Moshit Lindzen, Diana Drago Garcia, Joseph Green, Galit Eisenberg, Hava Gil-Henn, Arkaprabha Basu, Yan Lender, Shimon Weiss. Moshe oren. Yosef Yarden
Pubblicato in: Cell Reports, 2021, ISSN 2211-1247
Editore: Cell Press
DOI: 10.1016/j.celrep.2021.109181